David Rikard Martinsson Holmdahl
Fondateur chez Redoxis AB
Postes actifs de David Rikard Martinsson Holmdahl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Redoxis AB
 Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Président | 01/01/2007 | - |
| Fondateur | 01/01/2007 | - | |
| Karolinska Institutet | Corporate Officer/Principal | 22/12/2009 | - |
| University of Turku | Corporate Officer/Principal | 26/07/2011 | - |
Historique de carrière de David Rikard Martinsson Holmdahl
Anciens postes connus de David Rikard Martinsson Holmdahl
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| University of Lund | Corporate Officer/Principal | 01/01/2007 | 01/01/2007 |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Directeur/Membre du Conseil | 28/12/2009 | - |
Statistiques
Internationale
| Suède | 5 |
| Finlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Chairman | 1 |
| Founder | 1 |
Sectorielle
| Consumer Services | 4 |
| Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
Redoxis AB
Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
